Sponsored Links
BRIEF-AstraZeneca Naloxegol trial shows no imbalances in adverse effects
LONDON |
LONDON Feb 26 (Reuters) - AstraZeneca PLC : * Announces results from long-term safety trial of Naloxegol in patients with
opioid-induced constipation * The Naloxegol trial reported no imbalances in serious adverse events * Naloxegol commercialisation and launch in U.S. subject to
both FDA approval and DEA schedule determination
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters